CADL Long Trade Setup Breakdown!๐
โ
Stock: Candel Therapeutics, Inc. ( NASDAQ:CADL )
โ
Chart Timeframe: 30-Minutes
โ
Setup: Long Trade (Breakout Play)
๐ Technical Analysis & Key Levels
๐ Trendline Breakout Attempt
The price is testing a descending trendline resistance (Pink Line).
A breakout above this level could lead to bullish momentum.
๐ Support & Resistance Zones
Support: $8.25 (White Line) โ Strong base, tested multiple times.
Breakout Level: $9.00 (Yellow Line) โ Crucial resistance area.
First Target: $9.86 (Red Line) โ Previous resistance level.
Final Target: $10.97 (Green Line) โ Next major resistance.
๐ Trade Plan
Entry: Above $9.00 (Confirmation of Breakout)
Stop Loss: Below $8.25 (Previous Support)
Take Profit Levels:
๐ฏ TP1: $9.86
๐ฏ TP2: $10.97
๐ Trade Strategy
๐ Breakout Confirmation Needed:
If price closes above $9.00, it confirms strength for a long entry.
A strong volume increase on breakout will add conviction.
๐ Risk Management:
Risk-to-reward ratio looks favorable.
Stop loss at $8.25 ensures a controlled downside risk.
๐ Watch for Fakeouts:
If the price rejects $9.00 and falls back, avoid entry or exit early.
๐ Trade Alert Summary
๐ Bullish Setup โ Watching for a breakout above $9.00
๐ Potential Upside: $9.86 โ $10.97
โ ๏ธ Risk Level: Moderate โ Wait for confirmation before entering.
CADL trade ideas
CADL/USD โ 30-Min Long Trade Setup!๐ ๐
๐น Asset: CADL/USD
๐น Timeframe: 30-Min Chart
๐น Setup Type: Bullish Pennant Breakout
๐ Trade Plan (Long Position):
โ
Entry Zone: Above 10.47 USD (Breakout Confirmation)
โ
Stop-Loss (SL): Below 10.16 USD (Breakout Invalidated)
๐ฏ Take Profit Targets:
๐ TP1: 10.88 USD (First Resistance Level)
๐ TP2: 11.32 USD (Extended Bullish Target)
๐ Risk-Reward Ratio Calculation:
๐ Risk (SL Distance): Below 10.16 USD
๐ Reward to TP1: 10.88 USD
๐ Reward to TP2: 11.32 USD
๐ Technical Analysis & Strategy:
๐ Breakout Confirmation: A strong push above 10.47 USD signals bullish momentum.
๐ Pattern Formation: Bullish Pennant Breakout, indicating a potential continuation move.
๐ Key Support & Resistance Levels:
๐ข 10.16 USD โ Strong Support / Stop-Loss Level
๐ก 10.47 USD โ Breakout Zone / Entry Level
๐ด 10.88 USD โ First Profit Target / Resistance
๐ข 11.32 USD โ Final Target for Momentum Extension
๐ Momentum Shift Expected:
๐ If price stays above 10.47 USD, it could rally towards 10.88 USD and 11.32 USD.
๐ A high-volume breakout would strengthen the trend continuation.
๐ฅ Trade Execution & Risk Management:
๐ Volume Confirmation: Ensure strong buying volume above 10.47 USD before entering.
๐ Trailing Stop Strategy: Move SL to entry (10.47 USD) after TP1 (10.88 USD) is hit.
๐ฐ Partial Profit Booking Strategy:
โ Take 50% profits at 10.88 USD, let the rest run to 11.32 USD.
โ Adjust Stop-Loss to Break-even (10.47 USD) after TP1 is reached.
โ ๏ธ Fake Breakout Risk:
If price falls below 10.47 USD, wait for a retest before considering re-entry.
๐ Final Thoughts:
โ Bullish Setup โ Holding above 10.47 USD could lead to higher targets.
โ Momentum Shift Possible โ Watch for volume confirmation.
โ Favorable Risk-Reward Ratio โ 1:1.13 to TP1, 1:2.46 to TP2.
๐ก Stick to the plan, manage risk, and trade smart! ๐๐
๐ #StockTrading #CADLUSD #BreakoutTrade #TechnicalAnalysis #MarketTrends #ProfittoPath #DayTrading #MomentumStocks #SwingTrading #TradingView #LongTrade #TradeSmart #RiskManagement #StockBreakout #Investing #StockAlerts #ChartAnalysis ๐๐
CADL Bullish Surge: Targeting $14.49.CADL is demonstrating strong bullish momentum, breaking out with significant volume and reclaiming key levels. Entry near $10.13 with a target of $14.49 and a stop loss at $8.55 provides an excellent risk-reward ratio. Momentum indicators support a potential continuation to higher levels. Watching closely for sustained volume and price action for further confirmation.
Candel Therapeutics Stock ($CADL) Soars 352%Introduction:
In a groundbreaking development in the fight against pancreatic cancer, Candel Therapeutics ( NASDAQ:CADL ) has unveiled compelling data from its phase 2 clinical trial of CAN-2409. The therapy, designed to stimulate a robust anti-tumoral immune response, has demonstrated unprecedented improvements in survival rates among patients with non-metastatic pancreatic ductal adenocarcinoma (PDAC). With survival rates nearly tripling compared to standard-of-care (SoC) chemotherapy, CAN-2409 offers hope to patients facing this aggressive and notoriously difficult-to-treat cancer. The news led NASDAQ:CADL stock to surge with about 352% but is down by 4% as at the time of writing.
Unveiling the Data:
Candel Therapeutics ( NASDAQ:CADL ) recently announced updated interim data from its randomized phase 2 clinical trial of CAN-2409. The results, presented at the 2024 Society for Immunotherapy Annual Meeting, revealed staggering improvements in survival outcomes for patients with borderline resectable PDAC. The estimated median overall survival soared to 28.8 months among patients receiving CAN-2409, compared to a mere 12.5 months in the control group treated with SoC chemotherapy alone.
Moreover, at the 24-month mark, a remarkable 71.4% of CAN-2409-treated patients were still alive, contrasting starkly with the control group's survival rate of only 16.7%. Even at 36 months, the survival advantage persisted, with 47.6% of CAN-2409 recipients still alive, underscoring the therapy's potential to provide durable benefits for PDAC patients.
Mechanism of Action:
CAN-2409 operates by activating a potent anti-tumoral immune response within the pancreatic tumor microenvironment. Analysis of resected tumors revealed dense aggregates of immune cells, including cytotoxic tumor-infiltrating lymphocytes and dendritic cells, indicative of heightened immunogenicity following CAN-2409 administration. These findings suggest that CAN-2409 effectively harnesses the patient's own immune system to target and eradicate cancerous cells, thus offering a novel approach to combatting PDAC's formidable resistance mechanisms.
Safety Profile:
Crucially, CAN-2409 exhibited a favorable safety profile throughout the trial, with no dose-limiting toxicities or instances of pancreatitis reported. This underscores the therapy's potential to be administered safely alongside standard chemoradiation protocols, offering a promising avenue for integration into current treatment regimens for PDAC patients.
Implications for the Future:
The promising results from Candel Therapeutics' phase 2 trial of CAN-2409 represent a significant stride forward in the quest to improve outcomes for pancreatic cancer patients. With the therapy's ability to prolong and sustain survival rates, even in the face of a disease notorious for its aggressive nature and poor prognosis, CAN-2409 holds immense promise as a potential game-changer in the field of pancreatic cancer therapeutics.
Looking ahead, further clinical investigations and regulatory approvals will be crucial in bringing this innovative therapy to the forefront of pancreatic cancer treatment paradigms. If successful, CAN-2409 has the potential to revolutionize the standard of care for PDAC patients, offering newfound hope and extending lifespans for those grappling with this devastating disease.
Technical Outlook
Despite the spike in price by 352%, Candel Therapeutics NASDAQ:CADL is down by 7% in early premarket trading on Friday. the stock is trading above the 200-day Moving Average (MA) with a Relative Strength Index (RSI) of 88.50 indicating a strong overbought position for the stock.